Form 4: Arrowhead Pharmaceuticals CEO Sells Shares to Cover Tax Obligations

Arrowhead Pharmaceuticals CEO Christopher Anzalone sold 12,563 shares of common stock at an average price of $19.59 on December 23, 2024, to cover tax withholding obligations and pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• On December 23, 2024, Christopher Anzalone, CEO of Arrowhead Pharmaceuticals, sold 12,563 shares of the company's common stock.
• The shares were sold at a weighted average price of $19.59, with individual transactions ranging from $19.39 to $19.85.
• The sale was executed under a pre-existing 10b5-1 trading plan.
• A portion of the shares were disposed of to satisfy tax withholding obligations related to vested Restricted Stock Units (RSUs).
• Following the transaction, Anzalone directly owns 3,775,772 shares of Arrowhead Pharmaceuticals, which includes shares underlying RSUs subject to vesting conditions.

Sentiment

Score: 5

Explanation: The document describes a routine stock sale by the CEO, partly to cover tax obligations. The use of a 10b5-1 plan suggests the sale was pre-planned and doesn't necessarily reflect a negative outlook on the company. Therefore, the sentiment is neutral.

Industry Context

Sales by insiders are a common occurrence and are often related to personal financial planning or diversification. The use of a 10b5-1 trading plan suggests the sale was pre-planned and not based on current market information.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely to be minimal given the relatively small number of shares sold compared to the total outstanding shares.
• The sale to cover tax obligations related to RSUs suggests that management is being compensated with equity, which aligns their interests with those of shareholders.

Key Dates